Novosanis signs an agreement to provide MDxHealth a customized urine collection device


Novosanis today announced that it signed an agreement with MDxHealth to supply UrNCollect™, a customized version of the Company’s patented urine collection device called Colli-Pee™. The medical device facilitates accurate sample collection for urine-based tests. 

The privately-owned medical device company, Novosanis, and MDxHealth SA (Euronext: MDXH.BR) signed a supply agreement for a customized version of Novosanis’ first void urine collection device, Colli-Pee™. The device allows for a standardized, hygienic and user-friendly collection of the first 20ml of the urine stream and reduces lab errors by automating preservative mixing without additional handling.

“We are happy to initiate a collaboration with MDxHealth. Our Colli-Pee device will allow easy collection of standardized first void urine with less handling and no traditional pipetting. Everybody gains when the sample collection process is simplified and streamlined.” said Dr. Vanessa Vankerckhoven, CEO and co-founder of Novosanis.
Dr. Jan Groen, CEO MDxHealth, commented: “MDxHealth is pleased with Novosanis’ development of UrNCollectTM for our SelectMDx for Prostate Cancer IVD kit that will launch later this year. We expect the device to be more comfortable for patients and contribute to the test’s accuracy.”


Novosanis is an innovative developer and producer of medical devices adding value to the accuracy of diagnostics tests as well as drug delivery in the field of prevention, detection and treatment of infectious diseases and oncology.

Novosanis is a Belgian company endorsed on multiple occasions nationally and internationally for its solutions and is ISO13485 certified.

Novosanis prospers in user-friendly and clever medical devices meeting all regulatory and quality requirements for self-sampling and drug delivery solutions that improve accuracy and standardization while making handling easier, more consistent and more comfortable for the user.


Interested in a regular update of the Life Sciences and biotech sector in Flanders?